NCT06999733 - A Study Assessing KB801 for the Treatment of Stage 2 or 3 Neurotrophic Keratitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

October 31, 2026

Conditions

Neurotrophic Keratitis

Interventions

BIOLOGICAL

KB801

Ophthalmic suspension of replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-based vector delivering functional, full-length human nerve growth factor (NGF)

DRUG

Placebo

Vehicle

Trial Locations (6)

15219

NOT_YET_RECRUITING

UPMC Vision Institute, Pittsburgh

46290

NOT_YET_RECRUITING

Midwest Cornea Associates, Carmel

55305

RECRUITING

Minnesota Eye Consultants, Minnetonka

56308

RECRUITING

Vance Thompson Vision, Alexandria

91107

NOT_YET_RECRUITING

Azul Vision - California Eye Specialists Medical Group Inc., Pasadena

92617

NOT_YET_RECRUITING

University of California Irvine, Irvine